Regenerative medicine for the cornea.

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Tissue Engineering

Background:

• Conventional keratoplasty faces limitations for corneal disease treatment.
• Limbal transplantation for limbal stem cell deficiency requires long-term immunosuppression with significant risks.
• Cultured limbal or oral mucosal epithelial stem cells offer an alternative for ocular surface reconstruction.

Purpose of the Study:

• To review the current status of regenerative medicine for corneal diseases.
• To address the challenges of cell sheet fabrication in specialized centers.
• To introduce a novel cell transportation technique for clinical application.

Main Methods:

• Review of current literature on corneal regenerative medicine.
• Development of a cell transportation technique for clinical trials.
• Discussion of shared cell processing center models.

Main Results:

• Regenerative medicine, particularly using tissue-engineered cell sheets, shows promise for corneal repair.
• The high cost of cell processing centers (CPCs) is a barrier to widespread adoption.
• A developed cell transportation technique enables bridging hospitals for clinical trials.

Conclusions:

• Tissue-engineered oral mucosal epithelial cell sheets represent a viable regenerative therapy for corneal diseases.
• Sharing cell processing centers can standardize and disseminate regenerative therapies.
• The novel cell transportation technique is crucial for the clinical application and accessibility of these advanced therapies.